Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.
TO THE EDITOR
To date, the feasibility of nonmyeloablative stem cell transplantation (NST) from a human leukocyte antigen (HLA)-matched sibling donor (MSD) has been reported by many investigators. However, the issue of whether NST from a partially mismatched related donor (PMRD) is also feasible for patients who lack an MSD remains to be determined. In the major histocompatibility complex nonidentical hematopoietic stem cell transplantation (SCT) setting, two immunological HLA barriers must be overcome. One is the rejection barrier, or host-versus-graft (HVG) reaction; the other is the graft-versus-host (GVH) reaction. In myeloablative transplant settings, the incidence of graft-versushost disease (GVHD) or rejection has been reported to increase depending on HLA disparity in the GVH or HVG direction, respectively.
1,2 For GVHD, myeloablative bone marrow transplantation (BMT) from a 1-antigen-mismatched related donor may be feasible depending on the patient's situation. 3 Furthermore, successful transplantation from a 1-antigen-mismatched related donor using a reduced-intensity conditioning regimen has been reported recently. 4 However, transplantation from donors with more than one antigen mismatch is not a generally accepted treatment option. On the other hand, with respect to rejection, recipients who undergo NST are in a considerably different situation than recipients who undergo myeloablative SCT. In NST settings, even if graft rejection occurs, recipienttype hematopoietic cells are expected to recover, and therefore rejection does not result in early death in most cases. Therefore, the fact that a donor has HLA mismatches of X1 antigen in the HVG direction may not be a contraindication for NST.
Based on these observations, we assessed whether NST from PMRDs (1-antigen mismatch in the GVH direction and X1-antigen mismatch in the HVG direction) could be performed with a preconditioning regimen consisting of fludarabine, busulfan and anti-T-lymphocyte globulin (ATG), one of the standard conditioning regimens for NST.
From October 2000 to February 2002, six patients with hematologic malignancies underwent NST from PMRDs in Osaka University Hospital. The characteristics of the patients are shown in Table 1 . All donors had 5/6 serological matches in the GVH direction. One and five donors had 5/6 and 4/6 matches in the HVG direction, respectively. Following DNA typing of HLA, the disparity between donors and recipients was found to be even more extensive, as shown in Table 1 . The data of seven patients who underwent NST from an MSD between February 2000 and June 2002 were compared with those of the six recipients of NST from PMRDs. Institutional review board approval was obtained for the treatment protocol, and informed consent was obtained from patients and their families.
All patients who underwent transplantation from PMRDs or MSDs received a nonmyeloablative preparative regimen as previously described by Slavin et al, 5 with some modifications. In brief, fludarabine 30 mg/m 2 /day intravenously (i.v.) for 6 days (days À10 to À5), busulfan 4 mg/kg/day orally for 2 days (days À6 to À5) and rabbit ATG (Thymoglobuline; SangStat, Lyon, France) 0.25-1.00 mg/kg/day i.v. for 4 days (days À4 to À1) were administered. For GVHD prophylaxis in PMRD transplantation, two patients received cyclosporine (CsA) alone, two tacrolimus (FK506) alone, one FK506 þ methylprednisolone (mPSL) and one FK506 þ mycophenolate mofetil (MMF) ( Table 1 ). All patients who underwent transplantation from MSDs received CsA alone.
In PMRD transplantation, despite extensive mismatches in the HVG direction, no graft rejection occurred. Furthermore, there was no difference in the hematopoietic engraftment profile between PMRD and MSD recipients, although two of the PMRD recipients did not achieve an unsupported platelet count of greater than 50 Â 10 9 /l because of the development of fatal Correspondence thrombotic microangiopathy (TMA). Four of six patients developed Xgrade II acute GVHD during an early phase of transplantation (on days 7, 7, 11 and 19) ( Table 1) . Differences in ATG dose or in GVHD prophylaxis were not likely to have affected the outcome of acute GVHD. Two patients with grade III GVHD (UPN 265 and UPN 273) received mPSL and MMF against GVHD with little effect, and ultimately died of multiorgan failure following TMA on days 32 and 57, respectively. One patient (UPN 253) with chronic GVHD died of multiorgan failure due to TMA on day 261.
All five patients who had active disease at the time of transplantation achieved complete remission (CR) following transplantation. One patient with chronic myelomonocytic leukemia (UPN 242) had a hematologic relapse on day 41. This patient underwent retransplantation from another related donor and survives in CR.
After the transplantation, serial blood samples were analyzed to determine the degree of donor/recipient chimerism using polymerase chain reaction of informative microsatellite regions. 6 In PMRD transplantation, all of five patients in whom the chimerism status was assessed achieved 100% donor chimerism in T-cell and myeloid lineages by 2 weeks after transplantation (Figure 1, circles) . In contrast, all of five patients who underwent NST from MSDs and in whom the chimerism status was assessed showed mixed chimerism in both lineages to various degrees until 4-8 weeks after transplantation (Figure 1 , squares). T-cell chimerism analysis revealed that the percentage of donor T cells at 2 weeks in patients who received transplants from MSDs was significantly lower, with a median of 63.5% (range, 23-95%) (P ¼ 0.01, Mann-Whitney's U-test), compared with that of PMRD recipients. In patients with mixed chimerism who received transplants from MSDs, immunosuppressive agents were tapered gradually or rapidly depending on the extent of mixed chimerism, and the patients subsequently achieved complete donor T-cell chimerism by 12 weeks after transplantation (Figure 1 ).
The present study is the first to demonstrate that 100% donortype engraftment could be rapidly achieved in the HLAhaploidentical NST setting using a preconditioning regimen consisting of fludarabine, busulfan and ATG, although NST is considered to have a higher risk of graft rejection than myeloablative SCT. To date, only a few studies of NST from HLA-haploidentical (mismatch of greater than one antigen) donors have been reported. Sykes et al 7 performed BMT using a conditioning regimen consisting of cyclophosphamide, ATG and thymic irradiation, and using GVHD prophylaxis of CsA monotherapy. Four patients with chemoresistant lymphoma underwent transplantation, and three of them achieved engraftment. Donor/recipient mixed chimerism was observed in all patients, and greater than 50% of granulocytes/monocytes were recipient derived in two patients. O'Donnell et al 8 performed BMT using a protocol in which post-transplantation cyclophosphamide was added to a preconditioning consisting of cyclophosphamide, fludarabine, and 2 Gy total body irradiation. In all, 10 patients with various hematologic malignancies underwent transplantation, but only five of them achieved donor-type engraftment.
In the present study, although five of six donors had 4/6 serological matches, and three of six donors had 3/6 genetic matches in the HVG direction, no graft rejection was observed. In addition, full donor chimerism in all lineages was rapidly achieved without passing through a mixed chimerism state. Therefore, the preconditioning regimen consisting of fludarabine, busulfan and ATG, one of the standard regimens for NST, seems to be sufficiently immunosuppressive to enable the engraftment of fully HLA-mismatched donor cells, although the number of patients we treated was small. Thus, we consider that myeloablative regimens such as the use of very high doses of chemotherapeutic agents and total body irradiation, and special devices such as thymic irradiation or post-transplantation cyclophosphamide are not necessary for overcoming the rejection barrier due to HLA haplotype mismatching.
The second point we should emphasize is that a remarkable difference in the chimeric profile of T cells was observed between MSD and PMRD transplant recipients. Namely, PMRD transplant recipients had already achieved 100% donor T-cell chimerism at the time of engraftment (by 2 weeks after transplantation), whereas MSD transplant recipients remained in a T-cell mixed chimerism state until 4-8 weeks posttransplant.
9,10 However, the kinetics of acquisition of donor chimerism differ substantially according to the type of nonmyeloablative protocol employed. Schetelig et al 11 reported, in MSD transplant recipients using a fludarabine þ busulfan þ ATG regimen, that donor-type chimerism was increased slowly during the first several weeks, in agreement with our results in HLA-matched NST. However, there have been no reports about the difference in the kinetics of acquisition of donor chimerism between HLA-matched and -mismatched transplantation using the same protocol.
In conclusion, the fludarabine þ busulfan þ ATG preconditioning regimen enables donor-type engraftment in HLAhaploidentical NST. In addition, since full donor T-cell chimerism was achieved in an early phase of transplantation without passing through a state of mixed T-cell chimerism in PMRD NST recipients, acute GVHD tended to occur earlier and more seriously, and GVHD prophylaxis may therefore need to be intensified in this transplant setting. BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis Leukemia (2003 Leukemia ( ) 17, 2054 Leukemia ( -2055 Leukemia ( . doi:10.1038 TO THE EDITOR Chronic myeloid leukaemia (CML) is characterised by the presence of a t(9;22)(q34;q11) reciprocal translocation in over 90% of cases, leading to a Bcr-Abl fusion protein whose increased tyrosine kinase activity is essential for the pathogenesis of the disease. In most CML patients, the breakpoint on the BCR gene occurs in the major breakpoint cluster region (M-bcr), leading to e13a2 and/or e14a2 fusion transcripts and a Bcr-Abl protein of 210 kDa. Breakpoints outside M-bcr occur infrequently in CML, in either m-bcr, producing e1a2 fusion transcripts and a p190 KDa fusion protein, or in the m-bcr region, generating long e19a2 mRNA molecules and the larger p230 BcrÀAbl protein. Other atypical BCR-ABL transcripts with fusions such as e13a3, e14a3 or e6a2 are very rare and have been only occasionally described.
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We report here a second case of a Philadelphia(Ph)-positive CML patient with an e6a2 BCR-ABL fusion transcript.
A 65-year-old male patient who was previously fit presented in November 2002 with symptoms of anaemia, weight loss and night sweats. At that time, gingival hypertrophy was noted, but hepatosplenomegaly and lymphadenopathy were absent. His peripheral blood showed a haemoglobin concentration of 68 g/l and a platelet count of 88 Â 10 9 /l. The white blood cell (WBC) count was 157 Â 10 9 /l, with 63% myeloblasts, 5% promyelocytes, 3% metamyelocytes, 7% myelocytes, 7% neutrophils, 2% eosinophils, 11% basophils and 2% lymphocytes. The bone marrow morphology was consistent with myeloid blast crisis of CML. Standard cytogenetics by Giemsa banding revealed a typical t(9;22)(q34;q11) translocation in all eight metaphases examined, with no additional chromosomal abnormalities. Screening by fluorescent in situ hybridisation for BCR-ABL fusion was positive in 98 of 100 interphases. RNA was extracted using the RNeasyt kit (Qiagen, Crawley, UK), and cDNA was synthesised using Superscript II RNase Hreverse transcriptase (Invitrogen, Paisley, UK) and random hexamer oligonucleotides. An initial multiplex RT-PCR for BCR-ABL using standard protocols 4 proved to be negative for BCR-ABL amplification (Figure 1a) . Therefore, amplification reactions specific for p210, p190 and p230 BCR-ABL fusion transcripts were performed. Using primers BCR1 þ (5 0 -GAACTCGCAACAGTCCTTCGAC-3 0 ) and Abl3-(5 0 -GGTAC CAGGAGTGTTTCTCCAGACTG-3 0 ), the presence of a PCR product larger than the e1a2 but smaller than an e13a2 transcript was observed (Figure 1b) . This fragment was gel purified and upon automated sequencing was identified as an e6a2 fusion transcript. RT-PCR reactions with the same reverse primer on ABL and forward primers on BCR exons 9 (for p210-type transcripts) or 18 (for p230 type) proved to be negative, whereas the normal copies of both the ABL and BCR genes could be amplified from the patient's cDNA (data not shown).
